How to access Attruby from India — the named-patient import pathway, 2026

Name: How to access Attruby from India — the named-patient import pathway, 2026 | Reserve Meds
Published: 2026-04-23

By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23

An Indian patient — or a diaspora family supporting a relative in India — diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM) may receive a prescription for Attruby (acoramidis) from their treating cardiologist or heart-failure specialist. Attruby is FDA-approved (2024) for ATTR-CM and is developed by BridgeBio. As a newer TTR stabiliser, Attruby is generally not yet stocked through Indian hospital pharmacies for routine outpatient dispensing, which is why access runs through the personal-use or hospital-sponsored named-patient import pathway.

This guide explains the legal pathway, the documentation your cardiologist prepares, typical timing, indicative cost posture, and where Reserve Meds fits in.

The clinical situation

Attruby is an oral TTR stabiliser — a high-affinity small molecule that binds the TTR tetramer and slows the dissociation step that precedes amyloid fibril deposition in the myocardium. It is taken orally, twice daily. Attruby is the newer entrant in the stabiliser class (FDA-approved November 2024) and joined tafamidis (Vyndamax / Vyndaqel) as a disease-modifying option for ATTR-CM. Eligibility is anchored to a confirmed ATTR-CM diagnosis — typically scintigraphy (PYP / DPD bone-tracer imaging) with or without endomyocardial biopsy — plus AL-exclusion workup and, where indicated, genetic testing to distinguish hereditary from wild-type disease. Your cardiologist will establish baseline NYHA class, NT-proBNP, troponin, eGFR, and a long-term follow-up cadence. Attruby is oral, so the operational bottleneck is supply continuity and import-pathway set-up, not administration infrastructure.

Is Attruby legally importable into India?

Yes — through the CDSCO / Drugs Controller General of India (DCGI) personal-use and hospital-sponsored named-patient import frameworks. India has a well-established personal-use import mechanism regularly used for rare-disease and newly-approved therapies. A registered medical practitioner — or the patient on personal-use grounds with physician documentation — may request import of a medicine approved by a recognised reference authority where no clinically equivalent registered alternative exists. Attruby's 2024-vintage approval status supports the clinical-rationale case that a clinically equivalent registered alternative is not available in India.

How the pathway works, step by step

Consultation with your treating cardiologist. Documentation of ATTR-CM diagnosis, scintigraphy evidence, AL-exclusion workup, and a clinical rationale letter.
Baseline assessment. NYHA class, NT-proBNP, troponin, eGFR, and a genetic test result if hereditary ATTR is suspected.
CDSCO personal-use / named-patient application. The physician or hospital pharmacy files clinical rationale, patient reference, dosing plan (oral twice-daily), and chain-of-custody commitment.
US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure Attruby from authorised distribution under DSCSA.
Ambient shipment. Attruby tablets ship under controlled ambient conditions with chain-of-custody documentation and customs clearance support.
Arrival and dispensing. The hospital pharmacy releases the bottle to the patient with the cardiologist-guided monitoring and refill schedule.

What documentation your physician needs

Clinical rationale letter confirming ATTR-CM diagnosis and Attruby as the indicated therapy
Verification of Indian medical registration (NMC / state medical council)
Copy of PYP / DPD scintigraphy report; endomyocardial biopsy where available
AL-exclusion workup (serum/urine immunofixation, free light chains)
Baseline NYHA, NT-proBNP, eGFR
Hereditary-ATTR genetic report if relevant
Planned dosing schedule (oral twice-daily) and follow-up plan

Reserve Meds provides a physician documentation kit bundling the templates CDSCO reviewers and Indian customs officers typically expect for rare-disease cardiology named-patient imports.

Costs and timing

Attruby for ATTR-CM is a long-duration, chronic therapy, and the annual cost is substantial. Reference US cash-pay for an annual course typically sits in the high six-figure USD range. Reserve Meds operates on a drug-only reference basis and provides a transparent, itemised delivered quote — covering product, shipping, CDSCO documentation handling, customs clearance, and concierge coordination — at the start of intake. Figures are indicative, not a binding quote until intake is complete.

Indicative timing — not guaranteed — for first dispense after cohort intake opens is approximately 7–14 days from the moment a complete CDSCO application is submitted and customs processing begins. Refills ship on a rolling monthly or quarterly schedule.

Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.

A culturally-aware note: ATTR-CM often runs in families, and diaspora households frequently coordinate care and payment across the US, the Gulf, and India. Our concierge accepts cross-border invoicing from family members settling care in India from abroad.

Reserve Meds's role

Sourcing. Through our US-licensed specialty wholesale partner under DSCSA chain-of-custody.
Documentation. Regulatory package for your physician and CDSCO / customs review.
Logistics. Ambient-controlled shipment with customs clearance support.
Concierge case lead. A named point of contact coordinating long-term refills.

What we do not do: We are not the prescriber. We do not practise medicine. We are not the dispensing pharmacy. All clinical decisions remain with your treating cardiologist. We operate on a waitlist basis during pre-launch.

Frequently asked

Is this legal in India? Yes, when executed through the CDSCO personal-use / named-patient framework with appropriate documentation. See our trust and compliance page.

How does Attruby compare with Vyndamax (tafamidis)? Both are oral TTR stabilisers for ATTR-CM. Vyndamax is the long-established standard-of-care with extensive real-world follow-up and a once-daily regimen. Attruby is a newer (2024-approved) entrant dosed twice daily with a distinct binding profile. Head-to-head clinical data continue to accumulate; your cardiologist will select based on clinical picture, product availability, and cost.

Can diaspora family pay directly? Yes. Cross-border payment is common; we issue invoicing that family in the US, UK, UAE, Canada, Australia, and Singapore can settle directly.

Will insurance cover this? Cash-pay is the default. Some Indian private insurers and diaspora policies consider rare-disease imports case by case; we supply documentation for your submission but do not process insurance claims directly.

Next step — join the first-cohort waitlist

Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we enter intake for Attruby coordination in India.

Add me to the Attruby waitlist

Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. We are in pre-launch; service availability is limited to our first cohort and published timelines are indicative, not guarantees. Cash-pay. Export-only (US → overseas). Composite case examples. Not medical advice.

Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.